Vistagen Therapeutics (VTGN) Net Margin (2017 - 2025)
Historic Net Margin for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to 6237.29%.
- Vistagen Therapeutics' Net Margin fell 2163500.0% to 6237.29% in Q4 2025 from the same period last year, while for Dec 2025 it was 8486.84%, marking a year-over-year decrease of 13734500.0%. This contributed to the annual value of 10579.84% for FY2025, which is 78202500.0% down from last year.
- Vistagen Therapeutics' Net Margin amounted to 6237.29% in Q4 2025, which was down 2163500.0% from 7525.97% recorded in Q3 2025.
- Vistagen Therapeutics' Net Margin's 5-year high stood at 90900.0% during Q1 2025, with a 5-year trough of 42789.74% in Q1 2022.
- For the 5-year period, Vistagen Therapeutics' Net Margin averaged around 2354.04%, with its median value being 5913.21% (2024).
- Per our database at Business Quant, Vistagen Therapeutics' Net Margin plummeted by -361019600bps in 2022 and then soared by 967054900bps in 2025.
- Over the past 5 years, Vistagen Therapeutics' Net Margin (Quarter) stood at 3000.56% in 2021, then crashed by -81bps to 5422.89% in 2022, then surged by 72bps to 1545.01% in 2023, then plummeted by -290bps to 6020.94% in 2024, then decreased by -4bps to 6237.29% in 2025.
- Its last three reported values are 6237.29% in Q4 2025, 7525.97% for Q3 2025, and 6186.48% during Q2 2025.